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T-cell deficiency in immune complex glomerulonephritis. Mice
chronically infected with the virus of lymphocytic choriomeningitis
(LCM) develop immune complex glomerulonephritis. Others have
shown that adoptive immunization of these mice by the i.p. injec-
tion of syngeneic immune spleen cells terminates the chronic viral
carrier state. The present studies were designed to define the effec-
tor cell from the immune spleen responsible for adoptive immuni-
zation and to determine the effect of this procedure upon the
immune complex nephritis which occurs in LCM carrier mice. The
results indicate that the effector cell in adoptive immunization is a
T-cell that functions directly as a killer cell when transferred to
LCM carrier mice. Sixteen of nineteen adoptively immunized mice
examined had less immune complex material deposited in their
glomeruli than control unmanipulated litter mates. These data
demonstrate that this animal model of immune complex glomerulo-
nephritis is immunodeficient with respect to LCM virus-spe-
cific killer T-cells. Transfer of this cell population to the LCM
carrier mouse diminishes the animal's viremia and improves its
immune complex nephritis. In view of these observations, it is
suggested that the rationale for the use of immunosuppressive
therapy in spontaneously occurring glomerulonephritis should be
carefully reconsidered.
Deficit des lymphocytes T dans Ia glomérulonephrite des com-
plexes immuns. Les souris infectées de façon chronique par le virus
de Ia chorioméningite lymphocytaire (LCM) développent une gb-
mérubonephrite des complexes immuns. D'autres auteurs ont mon-
tré que l'immunisation passive de ces souris par l'injection intra-
póritonéale de cellules spléniques syngéniques immunes met un
terme a l'état de porteur chronique du virus. Les experiences
rapportées ont eu pour but de définir Ia cellule effectrice de Ia rate
immune responsable de l'immunisation passive et de determiner
l'effet de cette immunisation sur Ia néphrite des complexes immuns
qui survient chez Ia souris porteuse du virus LCM. Les rCsultats
indiquent que Ia cellule effectrice dans l'immunisation passive est
un lymphocyte T qui fonctionne directement comme une cellule K
quand il est transféré a une souris porteuse de LCM. Onze parmi
les quatorze souris ayant subi l'immunisation avaient moms de
complexes immuns deposes dans les glomérules que les animaux de
Ia même portée non traités. Ces résultats montrent que cc modéle
animal de glomérubonephrite des complexes immuns est immu-
nobogiquement déficitaire en Ce qui concerne les celluies K spéci-
fiques du virus LCM. Le transfert de cette population cellulaire a Ia
souris porteuse du virus LCM diminue Ia virémie de l'animai et
améliore sa nephrite des immuns complexes. En fonction de ces
observations 1 est suggéré que les bases logiques de I'emploi
d'immunosuppresseurs dans les glomerulonephrites de survenue
spontanCe soient soigneusement reconsidérées.
Researchers in the past suggested that chronic
glomerulonephritis was an immunologically me-
Received for publication May 7, 1976;
and in revised form November 10, 1976
© 1977, by the International Society of Nephrology.
318
diated disease [1, 2]. In the 1950's, this was clearly
shown by the classic studies of Germuth [3] and
Dixon [4] who used the injection of foreign proteins
to elucidate the pathogenesis of immune complex
nephritis (ICGN) in rabbits. Evidence that the con-
cepts of immune complex disease developed in ex-
perimental animals applied to humans was initially
provided by the observation of glomerular im-
munoglobulin and complement deposits in pa-
tients with glomerulonephritis [5]. Despite our bet-
ter understanding of the pathogenetic mechanisms
involved in ICGN, therapeutic endeavors are still
based upon the concept of immunosupression or
attenuation of the action of the mediators of in-
flammation [6, 7]. These therapeutic regimes are of
necessity non-specific and no regime has been
uniformly accepted.
A more effective method of treating immune com-
plex disease might be immunostimulatiori of the host
to promote a different means of handling or perhaps
eliminating antigens which cause ICGN. Over the
past 15 years it has been demonstrated that many dif-
ferent antigens are capable of inducing chronic ICGN.
In some cases, elimination of the antigen has been
associated with amelioration of the disease [8—Il].
The effect of antigen elimination, however, is variable;
in certain cases, improvement in the disease has not
occurred when antigen was removed [12—14]. In some
situations it is not conceivable that the antigen depos-
ited in immune complex disease could be removed
from the body [15—16]. This investigation is con-
cerned with the effect of termination of viremia (anti-
genemia) upon an animal model with spontane-
ously occurring ICGN.
In the experiments to be described, we will present
data demonstrating that the ICGN occurring in mice
chronically infected with lymphocytic choriomen-
ingitis virus (LCM) is associated with an LCM im-
mune killer T-cell deficiency.a The experiments to be
T-cell function may be broadly classifiçd as: 1) helper (modu-
lating B-cell production of humoral immunogbobulin) [17], 2)
killer (direct T-cell contact lysis of target cells) 118], or 3) suppres-
sor (preventing immune reactions of either the cellular or hu-
moral type) [19].
T-cell deficiency in immune complex nephritis 319
described utilize methods developed in other labora-
tories which allow either isolation of purified T-cell
populations [20—22] or selective elimination of T-cells
from a mixture of cell types [23]. When LCM virus
immune splenic T-cells are transplanted to the virus
infected mouse, adoptive immunization [24, 25] oc-
curs and LCM virus is eliminated from the circula-
tion and liver, although it may persist indefinitely in
the brain and renal tubular cells [26]. Our data show
that in the adoptively immunized mouse the immune
complex nephritis improves when compared to litter
mate controls. This occurs even though the virus
persists in certain tissues and is not totally eliminated
from the host [26]. The data in this report describe
the cell transfer procedures used to elucidate the spe-
cificity of the cellular defect and preliminary patho-
logic observations of the kidney from control and
adoptively immunized LCM carrier mice.
Methods
All mice were of the SWR/J strain originally ob-
tained from Jackson Laboratories (Bar Harbor, ME)
and bred in our animal quarters. The LCM virus
strain used was CA-1371, originally obtained from
Dr. Wallace Rowe at the National Institutes of
Health. Neonates were injected intracerebrally with
10 LD5O's of LCM virus to produce chronically
infected mice. They were weaned at one month of age
and used for experiments after two months of age.
Methods of preparation and separation of cell popu-
lations. Either thymus glands, femoral bone marrow,
or spleens were used to obtain various cell prepara-
tions. The spleen or thymus gland was placed in 10 ml
of minimal essential media with 10% fetal calf serum
(MEM-FCS) and the organ teased apart to free the
cells. To prepare bone marrow cell suspensions, the
femurs were removed and the marrow washed from
within the shaft using a 27-gauge needle and syringe.
The final volume of the suspensions was 10 ml for
each organ used. Cells were centrifuged at X200 g for
seven minutes (International PR6) and the super-
natant discarded. The cells obtained from each organ
used were washed one time with 10 ml of MEM-FCS
and finally resuspended in a volume of 1 ml of the
medium. The number of viable nucleated cells was
determined using the difference of the number of
cells which were trypan blue positive determined in
a separate cell count.
In certain experiments the whole spleen cell sus-
pension was fractionated into populations containing
primarily T-cells or primarily B-cells, using a nylon
wool column by methods available from the liter-
ature [22]. Briefly, 0.6 g of nylon wool obtained from
a Filtration Leukopheresis Set (Fenwal Laboratories,
Deerfield, IL) were firmly packed into a 10-mi plastic
syringe for each 108 cells to be placed upon the col-
umn. The column was washed with 50 ml of warm
MEM-FCS and allowed to incubate at 370 for 45 mm,
after which time an additional 50 ml of warm MEM-
FCS was passed through the column. The cell suspen-
sion was then placed upon the column followed by
0.5 to 1 ml of MEM-FCS to insure exposure of all
cells to the nylon, and the column was sealed. After
45 mm of incubation at 37° C, T-cells were eluted
from the column using 50 ml of 37° C MEM-FCS.
To obtain the nylon wool-adherent B-cell population,
the contents of the column were placed in a Petri dish
containing 20 ml of MEM-FCS. The nylon wool was
agitated and teased apart for several minutes, after
which time the nylon wool was discarded, and the
cells remaining in suspension were used as the nylon
adherent cell population. These cells were primarily
B-cells. The fractions obtained were centrifuged at
X200 g for seven minutes and resuspended in 1 ml of
MEM-FCS for each organ originally present. Cell
counts were performed as originally described.
Quantification of the number of B-cells in any cell
population was done utilizing an anti-mouse im-
munoglobulin antiserum conjugated with fluorescein.
One hundred microliters of a cell suspension was
incubated with 100 l of the fluorescein conjugate in
buffered normal saline (PBS) at 0 to 4° C for 30 mm
with gentle agitation. The cell suspension was washed
with 4 ml of MEM-FCS twice, and the fraction of
viable cells having surface immunoglobulin was
quantitated using a fluorescent microscope (Olym-
pus). Direct quantification of T-cells was not done.
Each adoptively immunized mouse received l0
viable cells of the appropriate cell suspension. The
effect of the cell population upon the mouse was
determined 28 days later unless otherwise stated. At
the time of autopsy, serum was collected for determi-
nation of complement-fixing anti-LCM antibody, and
various organs were examined by immunofluorescent
methods to determine the presence or absence of
LCM antigen in the tissues [27].
A microcomplement fixation test [28] was used to
titer serum anti-LCM antibody. Briefly, the test se-
rum was diluted 1: 10 and then serially by two's.
Twenty microliters of a test dilution was added to a
microtiter plate well, and an equal volume of LCM
antigen (Microbiological Associates, Bethesda, MD)
was added. The mixture was incubated at room tem-
perature for an hour and overnight at 4° C. Normal
guinea pig serum was used as a complement source;
by definition, one unit of complement was present in
20l of that dilution of normal guinea pig serum
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which lysed all of the sensitized sheep red blood cells
contained in 20tl of a cell suspension, which when
lysed by a 1: 10 dilution in distilled water had an
optical density of 0.25 0.01 in a 1-cm photometric
cell at 540 m light wavelength. Each test well had 1.4
U of complement added, and the mixture was in-
cubated at 370 C for one hour. Finally, 20tl of the
sensitized sheep red blood cell suspension was added
and the plates incubated an additional hour prior to
examination for lysis. The anti-LCM antibody titer
of the tested antiserum was one dilution less than that
at which all of the sheep red blood cells were lysed.
Based upon previous observations [26], the criteria
used to determine whether a cell population was able
to achieve adoptive immunization were: 1) clearing of
LCM immunofluorescent antigen from the liver of
the test animal and 2) the development of com-
plement-fixing LCM antibodies in serum. LCM virus
titrations were not performed in association with
these experiments.
All antisera used for immupofluorescent pro-
cedures were prepared by methods previously de-
scribed [27]. In certain experiments an antiserum
which killed mouse T-cells was used. This antiserum
was prepared by injecting a goat with a complete
Freund's adjuvant emulsion of rat cerebral cortex.
Antiserum from this goat has been previously charac-
terized [23] and shown to be cytotoxic for mouse T-
cells but not other cells from the lymphoid system of
the mouse.
Results
Shown in Table 1 are the results of adoptive immu-
nization experiments using cell populations from
mice immune or not immune to LCM virus. Immune
cells were obtained from the mothers of the LCM
carrier mice. Viral contamination in stool and urine
of the LCM carrier infects their mothers, who develop
a nonfatal infection and who uniformly become im-
mune to the virus. Nonimmune cells were obtained
from SWR/J mice which had not been exposed to
LCM virus. As can be seen, cells from nonimmune
donors were not able to achieve adoptive immuniza-
tion when transferred into LCM carrier mice. Sim-
ilarly, cells from the thymus gland or from the fe-
moral marrow of an immune donor were not able to
achieve adoptive immunization. In contrast, l0
whole spleen cells from the immune donors
uniformly adoptively immunized LCM carrier mice.
Adoptive immunization in these experiments was
manifested as the clearing of LCM viral antigen from
the liver and the presence of elevated titers of LCM
complement fixing antibody in the serum of the mice,
as shown in Figure 1. From these experiments, it may
Source
Nonimmune
donors
LCM
donors
Spleen 0/6a 15/15
Thymus gland 0/5 0/5
Femoral bone marrow 0/4 0/5
Number of LCM carriers adoptively immunized
Number of LCM carriers tested
be concluded that adoptive immunization requires
peripheral or "educated" lymphoid cells from an im-
mune donor. Administration of "uneducated" or
central cells from the thymus gland or from the bone
marrow, whether from immune donors or not, did
not result in adoptive immunization.
In Table 2 the results of the fractionation of whole
spleen cells into T and B-cells using a nylon column
are shown. There was an enrichment of immuno-
globulin bearing cells (B-cells) in the nylon adherent
cell population and a depletion of B-cells from the
fraction not adherent to the nylon column. In these
experiments, the flow rate through the nylon column
(20 to 30 mI/mm) was such that a number of B-cells
eluted with the nylon nonadherent cell population.
This resulted in a nylon adherent cell population rich
in "B" cells but probably devoid of "T" cells,
In Table 3 are shown the results of transfer of the
whole spleen cell preparation, the spleen cells not
adherent to the nylon wool column, and the cells
adherent to a nylon column and their ability to adop-
tively immunize mice chronically infected with LCM
virus. The whole spleen cell preparation was
uniformly able to adoptively immunize LCM carrier
mice. The cell population not adherent to the nylon
Table 1. Effect of source of lymphocytes and state of immunity on
adoptive immunization
+
0,
•g 160
0 0
80
1'::
10
Mice receiving Mice receiving Mice receiving
whole spleen T-cells B-cells
Fig. 1. Anti-LCM complement fixing antibody titers for mice receiv-
ing whole spleen cells; T-cells not adherent to a nylon column (con-
taminated with 20% B-cells) or B-cells which did adhere to the nylon
column (no T-cells present).
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Table 2. Effect of fractionation of whole spleen cells using nylo
c
n wool columns on the percent of cells w
ence microscopy
ith surface Ig seen by immunofluores-
Exp. no. Whole spleen cells, %
Cells not adherent to
nylon column, %
Cells adherent to
nylon column, %
1
2
3
4
5
35
51
33
43
55
15
24
19
30
28
65
60
83
100
82
43 + 43a 23 + 2.7k 78 7.lb
SCM.
b Mean statistically different (P < 0.005) from spleen cell population prior to exposure to nylon column.
column (1-cells) adoptively immunized 11 of 14 mice
tested. None of eleven mice injected with the nylon
adherent population (predominantly B-cells) were
adoptively immunized. Treatment of the unfraction-
ated spleen cell population with anti-rat brain anti-
serum and guinea pig complement resulted in the
loss of the ability to adoptively immunize an LCM
carrier mouse. The anti-rat brain antiserum kills
mouse T-cells [23]. Yet, the antiserum-treated whole
spleen cell population was able to reconstitute leth-
ally irradiated (1000 R) mice, indicating intact bone
marrow function. These data demonstrate that the
cells responsible for adoptive immunization of LCM
carrier mice are 1-cells which are inactivated by ex-
posure to antibrain associated theta antiserum [29].
The data presented thus far are consistent with a
mechanism of adoptive immunization involving ei-
ther helper T-cell function or killer T-cell function. In
an effort to elucidate which one of these two mecha-
nisms is responsible for adoptive immunization, a
very pure 1-cell population was obtained using a
slow flow rate (2 mI/mm) for elution of cells from the
nylon column. When this was done it was found that
the eluted cells were virtually free of immunoglobu-
lin-bearing cells (B-cells). Transfer of these cells to
Table 3. Effect of cell type on ability to adoptively immunize mice
chronically infected with LCM
Cell type
No. adoptively
immunized
/no. receiving
cell population
l0 viable whole spleen cells
Untreated
Treated with anti-rat brain
antiseruma
15/15
0/7b
l0 viable spleen cells not
adherent to nylon column 10/14
l0 viable spleen cells
adherent to nylon column 0/Il
Antiserum cytotoxic for mouse T-cells but not B-cells or hemato-
poietic precursors.
Cell preparation was able to reconstitute lethally irradiated mice.
LCM carrier mice resulted in adoptive immunization
as determined by a decrease of infectious virus in the
blood (seven of nine) or the absence of LCM antigen
in the liver in seven out of nine mice tested. Yet none
of these nine mice receiving very pure 1-cell popu-
lations had developed measurable complement-fixing
antibody in their blood (Fig. 2). Mice receiving whole
spleen cells from which the T-cell population was
originally derived did produce measurable anti-LCM
complement-fixing antibody in six of eight mice ex-
amined. Thus, the T-cell population responsible for
adoptive immunization functioned without the pro-
duction of antibody, indicating that these are direct
"killer" cells. It is noteworthy that these data also
imply nonfunction of LCM specific B-cells present in
LCM carrier mice; helper T-cells present in the im-
mune donors' spleen stimulated donor immune B-
Mice receiving Mice receiving
whole spleen T-cells
Fig. 2. Anti-LCM complement-fixing antibody titers for mice receiv-
ing whole spleen celLs or very pure T-cells containing less than 1%
B-cells.
0)C
x
0>
CE
=
a)(a
160 •
80 W
40
20
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cells
322 Hoffsten et al
cells to produce measurable quantities of anti-LCM
antibody. Yet the B-cells from the LCM carrier
mouse did not produce antibody when exposed to
LCM immune helper T-cells.
The effects of adoptive immunization with l0
whole spleen cells upon the immune complex glomer-
ulonephritis which occurs in LCM carrier mice are
illustrated in Figure 3. Shown are representative
glomeruli from a mouse adoptively immunized two
months previously (Fig. 3A) and its litter mate con-
trol (Fig. 3B). The control mouse had large amounts
of PAS+ material within the mesangial area of the
glomerulus. Also noteworthy is the relative increased
diameter of this glomerulus. The average glomerular
diameter of the ten largest glomeruli in a tissue sec-
tion having more than 150 glomeruli from this
mouse's kidney was I l2. Using a system to grade
PAS+ deposits in glomeruli from 0 to 4+, this
glomeruli received a grade of 3+. In contrast, the
adoptively immunized mouse had remarkably less
PAS+ material present in its mesangium and was
graded trace to 1 + (Fig. 3a). The average glomerular
diameter of the ten largest glomeruli on a tissue sec-
tion from the adoptively immunized mouse was 97t,
a value closer to the expected normal of 7l.t [30]. The
glomerular changes are remarkably uniform in any
given kidney section (Fig. 3c, 3d). The deposition of
immunoglobulin and complement as seen by immu-
nofluorescence microscopy paralleled the PAS+ de-
posits seen by light microscopy (Fig. 3e and 3f).
While immunoglobulin and complement deposits
were diminished in the adoptively immunized mice,
abnormal glomerular deposition of immune complex
material persisted even five months after adoptive
immunization (Fig. 3e).
In Table 4 are shown the results of 19 litter mate
pairs of mice, one of which had been adoptively
immunized. It may be seen that in 12 of 19 cases the
adoptively immunized mice had a smaller glomerular
diameter than the control, In six cases, the treated
mice were not distinguishable from the control, while
in one case the control was slightly smaller than the
treated. The extent of PAS+ glomerular deposits was
judged to be less in the adoptively immunized mouse
than in the control in 16 of 19 pairs examined. There
was a general correlation between glomerular diame-
ter and extent of PAS+ glomerular deposits, and in
most instances both parameters indicated less gb-
merular pathology in adoptively immunized mice.
Discussion
The data in this report demonstrate an LCM im-
mune T-cell deficiency associated with a spontane-
ously occurring immune complex glomerulonephri-
tis. Transplantation of purified splenic T-cells from
an immune donor to an LCM carrier mouse resulted
in clearing of virus from the blood and liver. This
clearing could be achieved even in the absence of
demostrable anti-LCM antibody production by the
adoptively immunized LCM carrier, thus indicating
that the transplanted T-cells did not function as
helper T-cells. Transplantation of unfractionated im-
mune spleen cells did result in adoptive immunization
with the production of anti-LCM antibody; the fact
that anti-LCM antibody was not produced when pu-
rified T-cells immune to LCM were transplanted sug-
gests that LCM specific B-cells in the LCM carrier
mouse are not functional. This observation demon-
strates that the LCM carrier mouse is not in a state of
pseudotolerance [311 in which the production of large
amounts of anti-LCM antibody is masked by an
equally large production of LCM antigen, resulting
in pathologic amounts of circulating immune com-
plex material. Although not conclusive, the findings
in this report suggest that the LCM carrier mouse
may be tolerant to LCM virus, a state terminated by
the transfer of LCM immune killer T-cells. These
observations are in complete agreement with a recent
report by Volkert et al [321. Also consistent with the
present observations is the recent report by Verroust
et al [33] demonstrating the occurrence of immune
complex nephritis in the nude mouse which has a
generalized T-cell deficiency.
Precise identification of the cells not adherent to
the nylon column was not done in the present work.
Mouse T-cells do not form spontaneous rosettes with
sheep red blood cells and therefore cannot be quan-
tified by the method used for human T-cells [34]. In
addition, mouse splenic T-cells are composed of a low
theta population [35], making accurate enumeration
by immunofluorescent technique difficult. Thus, our
conclusion that the effector cells for adoptive immu-
nization are T-cells is based on the T-cell specific
cytotoxicity of anti-theta antiserum [23]. Lym-
phocytes with F or complement receptors do not
carry surface theta antigen and are not inactivated by
anti-theta antiserum [36].
In studies on the pathogenesis of glomerulonephri-
tis in mice chronically infected with LCM virus, Old-
stone and Dixon [37] observed: I) glomerular depos-
its of mouse immunogbobulin and complement in
mice chronically infected with LCM virus, 2) that
circulating virus was complexed to immunoglobulin,
and 3) that 50% of the immunoglobulin eluted from
glomeruli in these mice was specific for LCM virus.
Based on these observations they conlcuded that mice
chronically infected with LCM virus were not im-
munologically tolerant to the virus, but instead pro-
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Fig. 3. Effect of adoptive immunization upon glomerular histopathology in mice chronically infected with LCM virus. Tissue from a mouse
adoptively immunized two months previously (a, c, e) and its unmanipulated litter mate control (b, d, f) are shown for comparison, a and
b show the increased amount of PAS+ material deposited in the control mouse and its markedly increased glomerular diameter (original
magnification X400, PAS stain). c and d show the uniformity of the lesion (original magnification X200, PAS stain). e and f are immuno-
fluorescent photomicrographs of glomeruli stained with an anti-mouse immunoglobulin fluorescein conjugate (original magnification X400);
while the adoptively immunized mouse has less immune complex material deposited in its glomerulus, it is still not normal.
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Table 4. Effect of adoptive immunization (Al) on glomerular histology
duced LCM specific antibody which complexed to
viral antigens and deposited in glomeruli. Their first
two observations are confirmed [27]. The observation
in the present report that the B-cells in LCM carrier
mice do not produce measurable amounts of serum
anti-LCM antibody during T-cell mediated adoptive
immunization provides a basis for further studies to
reconsider the question of tolerance to LCM virus in
this animal model.
The glomerulonephritis occurring in NZB X NZW
F1 hybrid mice [38] has recently been shown to in-
volve a T-cell defect, albeit somewhat different than
the lesion in the present report. A viral etiology for
the autoimmune disease of NZB X NZW mice has
been demonstrated [39, 40]. Associated with the ver-
tically transmitted viral infection is a progressive
diminution in suppressor T-cell function [41, 42], a
lesion hypothesized to be permissive for the develop-
ment of autoimmune disease.
In the present study adoptive immunization by cell
transfer may be conceptualized as a form of immu-
nostimulation and was effective in diminishing gb-
merular pathology in the animal model. In consid-
ering these observations, the rationale for
immunosuppressive therapy of immune complex
glomerulonephritis should perhaps be reevaluated.
Cyclophosphamide has been used to immunosup-
press mice chronically infected with LCM virus [27,
43]. The associated nephritis was prevented by pro-
longed cyclophosphamide administration which ap-
peared to function by a marked depression in an-
tibody production with serum immunoglobulin levels
being reduced to 25% of normal. Such extreme im-
munosuppression in humans has not been practical
and provides a plausible explanation for the discrep-
ancy in results obtained for drug treatment of mice
[27, 44] and humans [45]. For reasons not under-
stood, methylprednisolone treatment of LCM carrier
mice attenuates their nephritis [46], although drug
administration is not associated with alterations in
serum immunogbobulin or complement levels in the
treated mice. Thus, perhaps so-called immunosup-
pressive therapy with glucocorticoids exerts its occa-
sional beneficial effect on human immune complex
glomerulonephritis [47] by a mechanism quite unre-
lated to immunosuppression.
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